Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15133910 | 1.00 | GABRG2 (0.44) | GABRG2GABRB3GABRA5GABRA3NPC1 | |
| SCHEMBL15132509 | 0.86 | NPC1 (0.43) | NPC1CDK8 | |
| SCHEMBL1662304 | 0.85 | ALDH1A1 (0.40) | NPC1RAB9ACA12CA9CA1 | |
| SCHEMBL15132510 | 0.84 | ROCK2 (0.42) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14351835 | 0.81 | NPC1 (0.57) | NPC1RAB9A | |
| SCHEMBL1660988 | 0.74 | NPC1 (0.44) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL67941 | 0.72 | CA12 (0.68) | GABRG2GABRB3GABRA5GABRA3RAB9A | |
| SCHEMBL27715902 | 0.70 | CA12 (0.71) | GABRG2GABRB3GABRA5GABRA3CA12 | |
| SCHEMBL7827566 | 0.69 | HRH3 (0.46) | GABRG2GABRB3GABRA5GABRA3CA12 | |
| SCHEMBL13044211 | 0.68 | CA12 (0.56) | GABRG2GABRB3GABRA5GABRA3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | GABRG2 1222/4885GABRB3 1785/4885GABRA5 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.